首页> 外文OA文献 >MicroRNA-27b targets CBFB to inhibit differentiation of human bone marrow mesenchymal stem cells into hypertrophic chondrocytes
【2h】

MicroRNA-27b targets CBFB to inhibit differentiation of human bone marrow mesenchymal stem cells into hypertrophic chondrocytes

机译:microRNA-27b靶向CBFB,以抑制人骨髓间充质干细胞的分化为肥厚性软骨细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Human bone marrow-derived mesenchymal stem cells (hBMSCs) have chondrocyte differentiation potential and are considered to be a cell source for cell-transplantation-mediated repair of cartilage defects, including those associated with osteoarthritis (OA). However, chondrocyte hypertrophic differentiation is a major obstacle for the application of hBMSCs in articular cartilage defect treatment. We have previously shown that microRNA-27b (miR-27b) inhibits hypertrophy of chondrocytes from rat knee cartilage. In this study, we investigated the role of miR-27b in chondrocyte hypertrophic differentiation of hBMSCs. Methods Chondrogenic marker and microRNA expression in hBMSC chondrogenic pellets were evaluated using RT-qPCR and immunohistochemistry. The hBMSCs were transfected with miR-27b before inducing differentiation. Gene and protein expression levels were analyzed using RT-qPCR and western blot. Coimmunoprecipitation was used to confirm interaction between CBFB and RUNX2. Luciferase reporter assays were used to demonstrate that CBFB is a miR-27b target. Chondrogenic differentiation was evaluated in hBMSCs treated with shRNA targeting CBFB. Chondrogenic hBMSC pellets overexpressing miR-27b were implanted into cartilage lesions in model rats; therapeutic effects were assessed based on histology and immunohistochemistry. Results The hBMSCs showed typical MSC differentiation potentials. During chondrogenic differentiation, collagen 2 and 10 (COL2 and COL10), SOX9, and RUNX2 expression was upregulated. Expression of miR-140, miR-143, and miR-181a increased over time, whereas miR-27b and miR-221 were downregulated. Cartilage derived from hBMSC and overexpressing miR-27b exhibited higher expression of COL2 and SOX9, but lower expression of COL10, RUNX2, and CBFB than did the control cartilage. CBFB and RUNX2 formed a complex, and CBFB was identified as a novel miR-27b target. CBFB knockdown by shRNA during hBMSC chondrogenic differentiation led to significantly increased COL2 and SOX9 expression and decreased COL10 expression. Finally, miR-27b-overexpressing hBMSC chondrogenic pellets had better hyaline cartilage morphology and reduced expression of hypertrophic markers and tend to increase repair efficacy in vivo. Conclusion MiR-27b plays an important role in preventing hypertrophic chondrogenesis of hBMSCs by targeting CBFB and is essential for maintaining a hyaline cartilage state. This study provides new insights into the mechanism of hBMSC chondrocyte differentiation and will aid in the development of strategies for treating cartilage injury based on hBMSC transplantation.
机译:抽象背景人骨髓来源的间充质干细胞(的hBMSCs)具有软骨细胞的分化潜能,并且被认为是用于软骨缺陷,包括骨关节炎(OA)相关联的那些的细胞移植介导的修复的细胞源。然而,软骨细胞肥大分化为的hBMSCs的在关节软骨缺损治疗中的应用的主要障碍。我们以前曾表明,微小RNA-27B(的miR-27b)的抑制来自大鼠膝关节软骨细胞的肥大。在这项研究中,我们调查的hBMSCs的软骨细胞肥大分化的miR-27b的作用。使用RT-qPCR的和免疫组化方法软骨标记物和微小RNA表达在软骨的hBMSC粒料进行了评价。在分别的hBMSCs诱导分化之前的miR-27b的转染。使用RT-qPCR的和western印迹基因和蛋白表达水平进行分析。免疫共沉淀用于确认CBFB和RUNX2之间的互动。荧光素酶报告测定来证明,CBFB物是miR-27b的目标。软骨细胞分化与shRNA的目标CBFB处理的hBMSCs评价。软骨的hBMSC粒料过表达的miR-27b的植入模型大鼠软骨损伤;基于组织学和免疫组织化学的治疗效果进行了评估。结果显示的hBMSCs典型MSC分化潜能。在软骨细胞分化,胶原蛋白2和10(COL2和COL10),SOX9,和RUNX2表达上调。增加的miR-140,的miR-143和miR-181A的表达随时间推移,而miR-27B和miR-221被下调。软骨衍生的hBMSC和过表达的miR-27b中显示出COL2和SOX9的更高表达,却降低COL10,RUNX2的表达,和CBFB比对照软骨。 CBFB和RUNX2形成的复合物,和CBFB被鉴定为一种新型的miR-27b的目标。导致显著的hBMSC软骨细胞分化期间CBFB击倒shRNA的增加COL2和SOX9的表达和降低COL10表达。最后,的miR-27b中过表达的hBMSC软骨粒料具有更好透明软骨形态学和肥厚性标志物的表达降低,并且趋于增加体内修复功效。结论MIR-27B通过靶向CBFB起到预防的hBMSCs的肥厚性软骨的重要作用,是维持透明软骨的状态至关重要。这项研究提供了新的见解的hBMSC软骨细胞分化的机制,并在制定战略帮助治疗基础上的hBMSC移植软骨损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号